Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
about
CIViC databaseNeratinib in HER-2-positive breast cancer: results to date and clinical usefulnessRecent advances in the medical treatment of breast cancerTwenty years of anti-HER2 therapy-associated cardiotoxicityPrecision medicine in breast cancer: reality or utopia?A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.Epidemiology and survival outcome of breast cancer in a nationwide study.Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.HER2-positive breast cancer is lost in translation: time for patient-centered research.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.The role of neratinib in HER2-driven breast cancer.Neratinib for the treatment of HER2-positive early stage breast cancer.Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Targeting the Breast Cancer Kinome.Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.Targeted adjuvant therapy in breast cancer.Adjuvant trastuzumab: a 10-year overview of its benefit.ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breastNeratinib for the treatment of breast cancer.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects.Breast cancer treatment-induced cardiotoxicity.Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib.BET inhibitors as novel therapeutic agents in breast cancer.An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.Dual HER2 Blockade.Update Breast Cancer 2017 - Implementation of Novel Therapies.Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis.Some statistical considerations in the clinical development of cancer immunotherapies.Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?
P2860
Q27612411-7A0DAA15-0F09-4C57-86BA-1D641336C253Q28071303-98F3425C-DAE5-470C-B09E-0EB068686A48Q28078951-F17A9AAD-8E68-417D-AA23-00E4AAFD205BQ28079391-2A93F90F-1BA9-4DA9-A5B6-F3FD746CA6D2Q33809114-EC7D1AA0-04DF-4188-91AD-9646FF2C0B07Q37271711-8AC8D559-CED1-43BB-BE37-56B89930B8B2Q37725545-369FF0A2-671C-4E05-B479-FA132A06AB7EQ38373249-DD9AFBC9-AC3D-4F7E-856E-4AF172E339B9Q38648765-126C59B5-69C5-45B9-979A-A04D3E571E6DQ38661390-DA563245-1E06-488A-A2BE-FD74884F9F5FQ38664492-172647D6-FC5E-46D1-84F4-04D73A68794DQ38666768-214C82FE-FEDC-4C04-8EA5-AEF6E58436A5Q38677201-0A90483F-A2A2-4DD7-AF80-2623E00EF9EDQ38704133-0681D448-B3D1-4635-B213-3FBD5862FDDAQ38708134-FB4C7D67-3EE6-4936-9FFA-43C6D9CC5B0DQ38829087-4F5FC988-38BB-4754-8B38-BB09ADD9865DQ38836110-60CE289D-9A13-453C-92DD-BE3CF6DA0268Q38861026-8AFD97C1-EFF9-4257-A4F8-3E3CBC066C99Q38953228-30B65D57-3B5F-485A-A5F8-4D5B08D6286CQ38980703-C153F4D3-93DF-4A55-A4E6-409E51E36D78Q39018742-192A2B1C-C4FF-4BC6-B429-D70F40F71BCDQ39218140-E20FEBD3-6574-4FCE-9F9F-EE8651C195FDQ39333848-8C9456C8-FFCF-4172-9FFE-7CAE46B761E0Q39375196-0C31911D-A3AC-4A69-A1B3-BC94D2E9FB5AQ39390081-3EF7D821-DB88-41A3-A046-35AF29569719Q39428826-38D599F2-1876-4777-AE06-CE42B50B1736Q41601105-6C993493-719E-4545-9526-749E09A2D6CCQ42378528-3599C111-42C1-4737-A170-86E204040858Q46005851-253B4866-2E76-415B-BC2F-0C50B45A47A9Q46222280-D4C0F786-B56A-43EB-9E20-FFC7E9AFF884Q47110841-773E45C3-ED94-4F14-9F31-F45067204CA5Q47136119-7DB26EDF-F7C5-4B21-8B07-C6D59A84A0F0Q47138534-C5FBA471-A8F7-4B8C-BA47-00781401D0CDQ47368780-536C7A92-3477-432C-9174-3895A3928A85Q47594620-BF15B7BF-5730-475B-A29B-74D526498BFCQ48102534-6E8FB969-BF5D-4D29-991F-812BF5D507D7Q48308202-1D5BF482-1B39-4E38-80B3-65DC0FBE5087Q48369935-61482E0E-7B68-4C8E-A4B3-20172CC1F8E1Q49710712-6DEA2A50-24EB-4D3C-9C6E-8F99F9775F5BQ50043843-43FC3C55-5741-4AAE-94B0-4947C742D476
P2860
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@ast
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@en
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@nl
type
label
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@ast
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@en
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@nl
prefLabel
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@ast
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@en
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@nl
P2093
P50
P921
P3181
P1433
P1476
Neratinib after trastuzumab-ba ...... ebo-controlled, phase 3 trial.
@en
P2093
Alvin Wong
Angel Guerrero Zotano
Beverly Moy
Carlos H Barrios
Erhan Gokmen
Frankie A Holmes
Gladys Rodriguez
Graydon Harker
Hiroji Iwata
P304
P3181
P356
10.1016/S1470-2045(15)00551-3
P577
2016-03-01T00:00:00Z